临床试验对不同低分子肝素在急性冠状动脉综合征治疗效果的评价

The evaluation of clinical trials on different low molecular weight heparins in the efficacy of treatment in patients with acute coronary syndromes

临床试验研究使我们明确认识到低分子肝素在治疗急性冠状动脉综合征中已具有取代普通肝素的地位,成为急性冠状动脉综合征患者急性期治疗的新标准。但是,不同种类低分子肝素是有独特的化学、药代动力学及药效学特点的合成物。每一种制剂都有不尽相同的抗凝特点,可以通过抗凝血酶(抗Xa:Ⅱa的比值)及凝血酶介导的作用反应出来。低分子肝素在治疗急性冠状动脉综合征临床试验中显示出不同结果,说明一种制剂的临床结果不能扩展到另一种制剂,治疗上不能互换。

Clinical trials and research have made us clear and definite that the use of the low molecular weight heparins(LMWH) is superior, and including that subcutaneous injection is simple, without the need of monitoring the proceeding anticoagulant treatment, all indicates the LMWH in treating patients with acute coronary syndromes (ACS) has already replaced the unfractionated heparin, making it a new standard of the treatment in patients with acute coronary syndromes. But, different categories of LMWH are syntheses, which have dynamics and efficacy of medicine and special chemistry. Each kind of product has various functions that anticoagulant characteristics can pass the anticoagulant (the specific value of the anti-Xa : Ⅱa) . Clinical trials of LMWH treatment the ACS clinical trials show the different results, explaining a kind of product which can't spread to another product, and treatment can't be exchanged.